NKGen Biotech administers first dose of troculeucel for FTD under FDA-cleared compassionate use

NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in natural killer cell therapy, has taken a significant step in the treatment of frontotemporal ... Read More